Imatinib: In Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

By Cross Sarah A.   Lyseng-Williamson Katherine A.  

Drugs, Vol. 67, Iss. 17, 2007-01 ,pp. : 2645-2654

Adis International

Access to resources Recommend Favorite

Dasatinib: A Review of its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

By McCormack Paul L.   Keam Susan J.  

Drugs, Vol. 71, Iss. 13, 2011-09 ,pp. : 1771-1795

Adis International

Access to resources Recommend Favorite

A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

By Carpiuc Kimbach T   Stephens Jennifer M   Botteman Marc F   Feng Weiwei   Hay Joel W  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 16, 2007-11 ,pp. : 2775-2787

Informa Healthcare

Access to resources Recommend Favorite

Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure

By Hochhaus Andreas  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 18, 2007-12 ,pp. : 3257-3264

Informa Healthcare

Access to resources Recommend Favorite

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

By Soverini Simona   De Benedittis Caterina   Papayannidis Cristina   Paolini Stefania   Venturi Claudia   Iacobucci Ilaria   Luppi Mario   Bresciani Paola   Salvucci Marzia   Russo Domenico   Sica Simona   Orlandi Ester   Intermesoli Tamara   Gozzini Antonella   Bonifacio Massimiliano   Rigolin Gian Matteo   Pane Fabrizio   Baccarani Michele   Cavo Michele   Martinelli Giovanni  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 1002-1009

Blackwell Publishing

Access to resources Recommend Favorite